Please provide your email address to receive an email when new articles are posted on . Risk of death from all causes was similarly lower for patients on hemodialysis prescribed either allopurinol or ...

Credit: Getty Images. The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout. Allopurinol and febuxostat are ...

In contrast to CARES, FAST found that treatment with febuxostat was not associated with an increase in cardiovascular or all-cause death compared with allopurinol in patients with gout. Febuxostat ...

Please provide your email address to receive an email when new articles are posted on . “Very few published studies and data are available that provide any population-level comparative data of the ...

December 16, 2011 — A retrospective analysis of data from 222 hyperuricemic women with gout who had participated in phase 3 comparative trials showed that febuxostat, 80 mg/d, was more effective than ...

ORLANDO, FL—Patients with gout and coexisting cardiovascular disease saw no increase in major cardiovascular events while taking febuxostat versus allopurinol in the CARES trial, but investigators and ...

Nov. 17, 2005 (San Diego) — The investigative agent febuxostat is more effective for the management of gout than either allopurinol or placebo, according to investigators whose findings were presented ...

Hyperuricemia in patients with gout is most commonly treated with allopurinol. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, could potentially be a therapeutic alternative for ...

Febuxostat does not increase the risk of major cardiovascular outcomes compared with allopurinol in selected gout patients, according to new European study findings published online ahead of print in ...